Denosumab Demonstrates Superiority Over Zometa(R) In Pivotal Phase 3 Head-to-Head Tri

[News]

Amgen (Nasdaq: AMGN) announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

More... (http://www.medicalnewstoday.com/articles/156670.php)